[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. SEC Filing
This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.
The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.
Questo Schedule 13G 猫 presentato congiuntamente da Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC e Frank M. Sands e segnala una posizione passiva significativa in azioni ordinarie di Inhibikase Therapeutics. I soggetti dichiarante detengono beneficiariamente 10,950,000 azioni, pari al 14.7% della classe in circolazione, sulla base di 74,341,540 azioni in circolazione al 1掳 maggio 2025. La posizione 猫 riportata con potere di voto e di disposizione condivisi su 10,950,000 azioni e senza alcun potere di voto o di disposizione esclusivo.
La comunicazione esclude espressamente una warrant Serie A-1 per l'acquisto di 5,475,000 azioni e una warrant Serie B-1 per l'acquisto di 10,068,120 azioni perch茅 nessuna delle due 猫 esercitabile entro 60 giorni; ciascuna warrant contiene una clausola che impedisce la detenzione beneficiaria superiore al 19.99% immediatamente dopo l'esercizio. I soggetti dichiarante attestano che i titoli non sono detenuti al fine di modificare o influenzare il controllo dell'emittente.
Este Schedule 13G se presenta de forma conjunta por Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC y Frank M. Sands, y comunica una posici贸n pasiva significativa en acciones ordinarias de Inhibikase Therapeutics. Las personas informantes poseen a t铆tulo beneficiario 10,950,000 acciones, que representan el 14.7% de la clase en circulaci贸n, sobre la base de 74,341,540 acciones en circulaci贸n al 1 de mayo de 2025. La posici贸n se reporta con poder de voto y de disposici贸n compartido sobre 10,950,000 acciones y sin ning煤n poder exclusivo de voto o disposici贸n.
La presentaci贸n excluye expresamente un warrant Serie A-1 para comprar 5,475,000 acciones y un warrant Serie B-1 para comprar 10,068,120 acciones porque ninguno de los warrants es ejercitable dentro de 60 d铆as; cada warrant incluye una restricci贸n que impide una participaci贸n beneficiaria superior al 19.99% inmediatamente despu茅s del ejercicio. Las personas informantes certifican que los valores no se mantienen con la intenci贸n de cambiar o influir en el control del emisor.
鞚� Schedule 13G電� Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC 氚� Frank M. Sands臧� 瓿惦彊鞙茧 鞝滌稖頃� 瓴冹溂搿�, Inhibikase Therapeutics 氤错喌欤检潣 欷戩殧頃� 靾橂彊鞝� 歆�攵勳潉 氤搓碃頃╇媹雼�. 氤搓碃鞚鸽摛鞚� 鞁れ鞝侅溂搿� 10,950,000欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 5鞗� 1鞚� 旮办 氚滍枆欤检嫕靾� 74,341,540欤�毳� 旮办鞙茧 氚滍枆欤检嫕鞚� 14.7%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 歆�攵勳潃 10,950,000欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞙茧 氤搓碃霅橃棃瓿�, 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
氤� 鞝滌稖靹滊姅 Series A-1 鞗岆煱韸鸽 5,475,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ鞕� Series B-1 鞗岆煱韸鸽 10,068,120欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ毳� 氇呾嫓鞝侅溂搿� 鞝滌櫢頃╇媹雼�. 鞚措姅 霊� 鞗岆煱韸� 氇憪 60鞚� 鞚措偞鞐� 頄夓偓 臧�電ロ晿歆� 鞎婈赴 霑岆鞚措┌, 臧� 鞗岆煱韸胳棎電� 頄夓偓 歆來泟 鞁れ 氤挫湢臧� 19.99%毳� 齑堦臣頃橃 氇豁晿霃勲 頃橂姅 鞝滍暅鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚鸽摛鞚� 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼頃橂牑電� 氇╈爜鞚� 臧�歆�瓿� 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Ce Schedule 13G est d茅pos茅 conjointement par Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC et Frank M. Sands et signale une position passive significative sur les actions ordinaires d'Inhibikase Therapeutics. Les personnes d茅clarante d茅tiennent 脿 titre b茅n茅ficiaire 10,950,000 actions, repr茅sentant 14.7% de la cat茅gorie en circulation, sur la base de 74,341,540 actions en circulation au 1er mai 2025. La position est d茅clar茅e avec un pouvoir de vote et de disposition partag茅 sur 10,950,000 actions et sans aucun pouvoir de vote ou de disposition exclusif.
Le d茅p么t exclut express茅ment un warrant de s茅rie A-1 permettant d'acheter 5,475,000 actions et un warrant de s茅rie B-1 permettant d'acheter 10,068,120 actions parce qu'aucun de ces warrants n'est exer莽able dans les 60 jours ; chaque warrant contient une restriction emp锚chant une d茅tention b茅n茅ficiaire sup茅rieure 脿 19,99% imm茅diatement apr猫s exercice. Les personnes d茅clarante certifient que les titres ne sont pas d茅tenus dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G wird gemeinsam eingereicht von Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC und Frank M. Sands und meldet eine bedeutende passive Beteiligung an den Stammaktien von Inhibikase Therapeutics. Die meldenden Personen besitzen wirtschaftlich 10,950,000 Aktien, was 14.7% der ausstehenden Klasse entspricht, basierend auf 74,341,540 ausstehenden Aktien zum 1. Mai 2025. Die Position wird mit gemeinsamem Stimm- und Verf眉gungsrecht 眉ber 10,950,000 Aktien gemeldet; es bestehen keine alleinigen Stimm- oder Verf眉gungsrechte.
Die Einreichung schlie脽t ausdr眉cklich ein Series A-1-Warrant zum Kauf von 5,475,000 Aktien und ein Series B-1-Warrant zum Kauf von 10,068,120 Aktien aus, da keines der Warrants innerhalb von 60 Tagen aus眉bbar ist; jedes Warrant enth盲lt eine Beschr盲nkung, die einen wirtschaftlichen Besitz von mehr als 19,99% unmittelbar nach Aus眉bung verhindert. Die meldenden Personen best盲tigen, dass die Wertpapiere nicht gehalten werden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
- Clear disclosure of a material position: 10,950,000 shares representing 14.7% of the class
- Voting and dispositive power are specified (shared voting/dispositive power of 10,950,000; sole power 0)
- Warrant interests disclosed and excluded with stated exercise caps, improving transparency around potential dilution or ownership changes
- None.
Insights
TL;DR: Sands group reports a 14.7% shared stake (10.95M shares) in IKT; warrants are excluded from current beneficial ownership.
The Reporting Persons disclose a material passive stake of 10,950,000 shares in Inhibikase representing 14.7% of the class on the stated share count basis. The cover pages show shared voting and dispositive power only, with no sole control. The filing clarifies that Series A-1 and Series B-1 warrants (5,475,000 and 10,068,120 shares respectively) are excluded because they are not exercisable within 60 days and contain exercise ownership caps of 19.99%. For investors, this is a clear, material ownership disclosure but is presented as passive under Schedule 13G rules.
TL;DR: Joint filing by fund, manager and individual reports shared powers and disclaims intent to influence issuer control.
The Schedule 13G is filed jointly by the fund, its investment manager and an individual with ultimate voting/investment power, reflecting typical reporting structure: Sands Pulse Fund II holds the economic interest; Sands Capital Alternatives is the manager; Frank M. Sands holds ultimate authority. The statement includes an explicit certification that the securities were not acquired to change or influence control. The filing also discloses the organization and jurisdiction of each Reporting Person and the principal business address for the reporting entities.
Questo Schedule 13G 猫 presentato congiuntamente da Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC e Frank M. Sands e segnala una posizione passiva significativa in azioni ordinarie di Inhibikase Therapeutics. I soggetti dichiarante detengono beneficiariamente 10,950,000 azioni, pari al 14.7% della classe in circolazione, sulla base di 74,341,540 azioni in circolazione al 1掳 maggio 2025. La posizione 猫 riportata con potere di voto e di disposizione condivisi su 10,950,000 azioni e senza alcun potere di voto o di disposizione esclusivo.
La comunicazione esclude espressamente una warrant Serie A-1 per l'acquisto di 5,475,000 azioni e una warrant Serie B-1 per l'acquisto di 10,068,120 azioni perch茅 nessuna delle due 猫 esercitabile entro 60 giorni; ciascuna warrant contiene una clausola che impedisce la detenzione beneficiaria superiore al 19.99% immediatamente dopo l'esercizio. I soggetti dichiarante attestano che i titoli non sono detenuti al fine di modificare o influenzare il controllo dell'emittente.
Este Schedule 13G se presenta de forma conjunta por Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC y Frank M. Sands, y comunica una posici贸n pasiva significativa en acciones ordinarias de Inhibikase Therapeutics. Las personas informantes poseen a t铆tulo beneficiario 10,950,000 acciones, que representan el 14.7% de la clase en circulaci贸n, sobre la base de 74,341,540 acciones en circulaci贸n al 1 de mayo de 2025. La posici贸n se reporta con poder de voto y de disposici贸n compartido sobre 10,950,000 acciones y sin ning煤n poder exclusivo de voto o disposici贸n.
La presentaci贸n excluye expresamente un warrant Serie A-1 para comprar 5,475,000 acciones y un warrant Serie B-1 para comprar 10,068,120 acciones porque ninguno de los warrants es ejercitable dentro de 60 d铆as; cada warrant incluye una restricci贸n que impide una participaci贸n beneficiaria superior al 19.99% inmediatamente despu茅s del ejercicio. Las personas informantes certifican que los valores no se mantienen con la intenci贸n de cambiar o influir en el control del emisor.
鞚� Schedule 13G電� Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC 氚� Frank M. Sands臧� 瓿惦彊鞙茧 鞝滌稖頃� 瓴冹溂搿�, Inhibikase Therapeutics 氤错喌欤检潣 欷戩殧頃� 靾橂彊鞝� 歆�攵勳潉 氤搓碃頃╇媹雼�. 氤搓碃鞚鸽摛鞚� 鞁れ鞝侅溂搿� 10,950,000欤�毳� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 5鞗� 1鞚� 旮办 氚滍枆欤检嫕靾� 74,341,540欤�毳� 旮办鞙茧 氚滍枆欤检嫕鞚� 14.7%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 歆�攵勳潃 10,950,000欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞙茧 氤搓碃霅橃棃瓿�, 雼弲 鞚橁舶甓� 霕愲姅 雼弲 觳橂秳甓岇潃 鞐嗢姷雼堧嫟.
氤� 鞝滌稖靹滊姅 Series A-1 鞗岆煱韸鸽 5,475,000欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ鞕� Series B-1 鞗岆煱韸鸽 10,068,120欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ毳� 氇呾嫓鞝侅溂搿� 鞝滌櫢頃╇媹雼�. 鞚措姅 霊� 鞗岆煱韸� 氇憪 60鞚� 鞚措偞鞐� 頄夓偓 臧�電ロ晿歆� 鞎婈赴 霑岆鞚措┌, 臧� 鞗岆煱韸胳棎電� 頄夓偓 歆來泟 鞁れ 氤挫湢臧� 19.99%毳� 齑堦臣頃橃 氇豁晿霃勲 頃橂姅 鞝滍暅鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚鸽摛鞚� 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼頃橂牑電� 氇╈爜鞚� 臧�歆�瓿� 氤挫湢霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Ce Schedule 13G est d茅pos茅 conjointement par Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC et Frank M. Sands et signale une position passive significative sur les actions ordinaires d'Inhibikase Therapeutics. Les personnes d茅clarante d茅tiennent 脿 titre b茅n茅ficiaire 10,950,000 actions, repr茅sentant 14.7% de la cat茅gorie en circulation, sur la base de 74,341,540 actions en circulation au 1er mai 2025. La position est d茅clar茅e avec un pouvoir de vote et de disposition partag茅 sur 10,950,000 actions et sans aucun pouvoir de vote ou de disposition exclusif.
Le d茅p么t exclut express茅ment un warrant de s茅rie A-1 permettant d'acheter 5,475,000 actions et un warrant de s茅rie B-1 permettant d'acheter 10,068,120 actions parce qu'aucun de ces warrants n'est exer莽able dans les 60 jours ; chaque warrant contient une restriction emp锚chant une d茅tention b茅n茅ficiaire sup茅rieure 脿 19,99% imm茅diatement apr猫s exercice. Les personnes d茅clarante certifient que les titres ne sont pas d茅tenus dans le but de modifier ou d'influencer le contr么le de l'茅metteur.
Dieses Schedule 13G wird gemeinsam eingereicht von Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC und Frank M. Sands und meldet eine bedeutende passive Beteiligung an den Stammaktien von Inhibikase Therapeutics. Die meldenden Personen besitzen wirtschaftlich 10,950,000 Aktien, was 14.7% der ausstehenden Klasse entspricht, basierend auf 74,341,540 ausstehenden Aktien zum 1. Mai 2025. Die Position wird mit gemeinsamem Stimm- und Verf眉gungsrecht 眉ber 10,950,000 Aktien gemeldet; es bestehen keine alleinigen Stimm- oder Verf眉gungsrechte.
Die Einreichung schlie脽t ausdr眉cklich ein Series A-1-Warrant zum Kauf von 5,475,000 Aktien und ein Series B-1-Warrant zum Kauf von 10,068,120 Aktien aus, da keines der Warrants innerhalb von 60 Tagen aus眉bbar ist; jedes Warrant enth盲lt eine Beschr盲nkung, die einen wirtschaftlichen Besitz von mehr als 19,99% unmittelbar nach Aus眉bung verhindert. Die meldenden Personen best盲tigen, dass die Wertpapiere nicht gehalten werden, um die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Inhibikase (IKT) shares does Sands Capital report owning?
What percentage of Inhibikase does the 10,950,000 shares represent?
Do the Reporting Persons have sole voting or dispositive power over these shares?
Are Series A-1 or B-1 warrants included in the beneficial ownership calculation?
Is there an ownership cap associated with the warrants?
Which entities and individuals jointly filed this Schedule 13G for IKT?
